Clay Siegall’s venture to cancer treatment

Cancer has been on the list of the leading killer diseases since time immemorial. Research shows that in the United States approximately more than 1.5 million individuals are diagnosed with cancer with over 500000 succumbing to the disease. A study conducted in the year 2014 revealed that 14.5 million Americans were diagnosed with cancer. The study further went onto suggest that this number would clock 19 million in just under a decade. This research led to visionaries such as Clay Siegall to further hasten research on cancer treatment and diagnostics in order to reverse this trend. Since time immemorial chemotherapy and radiation have the preferred methods of handling cancer but haven’t really been of great significance. Through advancements in the field of human genetics, doctors, researchers, and geneticists have joined hands in a drive to devise new methods of cancer treatment and diagnostics.

His passion and visionary life has drove Dr. Clay Siegall to devote his time and funds into companies that are pacesetters in genetic research including Seattle Genetics, where he is the current President and CEO. Through these funded projects in medical and scientific research, doctors are now able to predict and pinpoint errors in the DNA code. This has been enabled through research by Professor Dame Sally Davies on whole genome sequencing(WGS). Currently, England’s Chief Medical Officer, Professor Sally’s research has enabled identify effective treatments to over 31,000 patients. WGS can help identify any slight error in the over 20,000 genes in a human body thus identifying cancer in its early stages. Since each individual has a unique DNA code, WGS can enable a doctor recommend a specific treatment procedure for a specific individual.

Other than the active roles Dr. Clay Siegall has in Seattle Genetics, he is also one of its co-founders. He is also a graduate of the University of Maryland with a bachelors in Zoology and also has a Ph.D. from George Washington University in the field of genetics. His drive to venture into cancer treatment and diagnostics was triggered after seeing the suffering his father went through when he was 19 years of age and later succumbed to it when he was 24.